deltatrials
Active Not Recruiting INTERVENTIONAL NCT04573023

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Sponsor: JCR Pharmaceuticals Co., Ltd.

Conditions Mucopolysaccharidosis II
Interventions Idursulfase JR-141 JR-141 or Idursulfase
Updated 33 times since 2020 Last updated: Apr 16, 2026 Started: Feb 14, 2022 Primary completion: Oct 31, 2027 Completion: Oct 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Mucopolysaccharidosis II and is currently ongoing. JCR Pharmaceuticals Co., Ltd. leads this study, which shows 33 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Jun 2025 · 4 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – ~Apr 2026 · 51 days · monthly snapshotApr 21, 2026 – present · 2 months · daily API

Change History

33 versions recorded

  1. Apr 21, 2026 — Present [daily]

    Active Not Recruiting

    Phase: PHASE3 → None

  2. Mar 2026 — Apr 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Feb 2026 — Mar 2026 [monthly]

    Active Not Recruiting PHASE3

  4. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE3

  5. Oct 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

▶ Show 28 earlier versions

  1. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE3

  2. Jun 2025 — Sep 2025 [monthly]

    Recruiting PHASE3

  3. Feb 2025 — Jun 2025 [monthly]

    Recruiting PHASE3

  4. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE3

  5. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE3

  6. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  7. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE3

  8. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  9. Feb 2024 — Apr 2024 [monthly]

    Recruiting PHASE3

  10. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE3

  11. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE3

  12. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE3

  13. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  14. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  15. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  16. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  17. Apr 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  18. Jan 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  19. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  20. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  21. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  22. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  23. Jan 2022 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE3

  24. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE3

  25. Sep 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE3

  26. Jan 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE3

  27. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

  28. Oct 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.

Contact Information

Sponsor contact:
  • JCR Pharmaceuticals Co., Ltd.
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Afula, Israel , Ankara, Turkey (Türkiye) , Barcelona, Spain , Bogotá, Colombia , Bron, France , Buenos Aires, Argentina , Chapel Hill, United States , Chicago, United States , Giessen, Germany , Hamburg, Germany and 14 more locations